December 2, 2024 8:05am

After 3 negatives, 1 holiday and 6 positive closes in past 2 weeks

Pre-open Indications: 5 Positive 

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened, might or will happen behind the headline today!

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

Friday’s night’s … RegMed Investors (RMi) Closing Bell: trade light, a drink? … https://www.regmedinvestors.com/articles/13716

 

Monday : The pre-open Dow futures DOWN -0.07% or (-30 points), the S&P futures are DOWN -0.05% or (-3 points) and the Nasdaq futures are UP +0.02% or (+4 points)

  • Index futures are thinly mixed with 2 slightly lower on Monday, 12/2;
  • European markets were higher,
  • Asia-Pacific markets traded mostly higher.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Friday: The Dow closed UP +188.59 points or +0.42%, the S&P closed UP +33.64 points or +0.56% while the Nasdaq closed UP +157.69 points or +0.83%

  • Friday’s advance/decline line ended with a negative close at the close of 15 incliner, 16 decliners and 4 flats
  • Last week, the Dow added 1.4% this week, bringing its gain for November to 7.5%, the S&P 500 and Nasdaq each advanced 1.1%,
  • November, the Dow ended +7.5 higher, the S&P +1.1% and the Nasdaq +1.1%. for the month, the Dow ended +5% and the S&P +6%.
  • The small cap-focused Russell 2000 surged 10.8% this month, helped by a gain of +1.2% for the week.

Economic Data Docket: economic data on manufacturing and construction spending

  • S&P Global US manufacturing PMI, November final (48.8 expected, 48.8 previously); Construction spending month-over-month, October (0.2% expected, +0.1% previously); ISM Manufacturing, November (47.6 expected, 46.5 previously); ISM prices paid, November (54.8 expected)

 

Q4/24: 1st session

  • November 10 negative and 9 positive closes
  • October: 8 positive and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context 

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed down -$0.67 with a positive +$4.02 or +1.59% pre-open

Blueprint Medicine (BPMC +$1.28 after Thursday and Wednesday’s +$0.47 after Tuesday’s +$0.76 after Monday’s -$0.28 with a positive +$1.62 or +1.68% pre-open

CRISPR Therapeutics (CRSP +$0.33 after Thursday and Wednesday’s +$1.53 after Tuesday’s -$1.09 after Monday’s +$2.52 with a +$0.17 or +0.31% pre-open

Moderna (MRNA +$0.33 after Thursday, Wednesday’s +$1.34 after Tuesday’s -$1.61 after Monday’s +$2.56 with a positive +$0.25 or +0.58% pre-open

Vericel (VCEL) closed up +$0.38 with a positive +$1.66 or +2.86% pre-open

 

The BOTTOM LINE: Trending or bending? …. A little bit of each!

I seem to be writing/saying with a question followed by a question …

  • Do we need to brace ourself for giving up some gains followed by another question.
  • Is this market “bubblicious” my concerns are macroeconomic and valuation.

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.